Pedro Alberto García-Hernández

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

Alan J. Garber, Robert R. Henry, Robert E. Ratner et al. · The Lancet · 2008 · 1.1K citations

Medicine, Endocrinology, Pharmacotherapy +13

Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures

Per Aspenberg, Harry K. Genant, Torsten Johansson et al. · Journal of Bone and Mineral Research · 2009 · 510 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +17

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · The Lancet Diabetes & Endocrinology · 2017 · 292 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · Diabetes Care · 2018 · 238 citations

Medicine, Pharmacology, Pharmacotherapy +17

Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure

Robert R. Recker, Pierre D. Delmas, Johan Halse et al. · Journal of Bone and Mineral Research · 2007 · 223 citations

Medicine, Pharmacotherapy, Bioavailability +16